Ads
related to: sanofi pharmaceuticals- Careers
Join our Mission to Improve
the Lives of Patients.
- Approved Medicines
See the Approved Treatments
Using Our Antibody Science.
- Antibody Science
Explore Our Unique Platforms
For Creating Antibody Treatments.
- Pipeline
Review our Pipeline and
See How We're Changing Treatment.
- Careers
Search results
EuroAPI appoints mediator to help restructure pile of debt, shares drop
Reuters· 12 hours ago, opens new tab has engaged a third-party mediator, known as a mandataire ad hoc, to handle financing discussions with creditors as it struggles to serve a growing pile of debt. , opens new ...
Head-To-Head Survey: Ionis Pharmaceuticals (NASDAQ:IONS) versus Nurix Therapeutics (NASDAQ:NRIX)
ETF DAILY NEWS· 3 days agoNurix Therapeutics (NASDAQ:NRIX – Get Free Report) and Ionis Pharmaceuticals (NASDAQ:IONS – Get Free Report) are both medical companies, but which is the better stock? We ...
Navigating 14 Analyst Ratings For Regeneron Pharmaceuticals - Regeneron Pharmaceuticals...
Benzinga· 3 days agoPharmaceuticals analyst ratings. About Regeneron Pharmaceuticals Regeneron Pharmaceuticals discovers, develops, and commercializes products ...
Goldman Sachs raises Royalty Pharma stock target on deal activity By Investing.com
Investing.com· 8 hours agoOn Friday, Goldman Sachs (NYSE:GS) updated its financial model for Royalty Pharma (NASDAQ:RPRX),...
Meme Mania Meets Medicine: 3 Biotech Stocks Primed to Soar
InvestorPlace· 9 hours agoIn a meme frenzy, any positive news related to a company has a magnified impact on the stock price....
Climate change to drive multiple sclerosis cases, fuel treatment market: Report
Investing.com· 15 hours agoNew Delhi, June 7 (IANS) Climate change is likely to have a significant impact on the rise in...
TEVA Stock Rises 135% in a Year: What's Driving the Recovery?
Zacks· 4 days agoTeva Pharmaceutical Industries Limited’s (TEVA Quick QuoteTEVA - Free Report) revenues have suffered...
Why Counterfeit Ozempic Is a Global-Growth Industry
Vanity Fair· 3 days agoMeanwhile, the cost of the GLP-1 drugs—roughly $12,000 a year without insurance—places them beyond the reach of most patients who need them. Apovian’s...
GSK Stock Dives After Judge Allows Zantac Cancer Lawsuits To Go Forward
Investopedia· 4 days agoAmerican depositary receipts (ADRs) of GSK Plc (GSK) tumbled in intraday trading Monday after a...
These Biotech Stocks Hit New Highs, Did You Reap The Rewards?
RTT News· 8 hours agoThe following compilation represents a selection of stocks featured on our website that reached new 52-week high levels during the current week. Protagonist is a clinical-stage biopharmaceutical ...